Does Heparin Coating Improve Patency or Reduce Infection of Tunneled Dialysis Catheters?

被引:48
|
作者
Jain, Gaurav [1 ]
Allon, Michael [1 ]
Saddekni, Souheil [2 ]
Barker-Finkel, Jill [3 ]
Maya, Ivan D. [1 ]
机构
[1] Univ Alabama, Intervent Nephrol Sect, Div Nephrol, Birmingham, AL 35294 USA
[2] Univ Alabama, Div Intervent Radiol, Birmingham, AL 35294 USA
[3] Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA
关键词
OUTCOMES; ACCESS; TRIAL;
D O I
10.2215/CJN.03920609
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Tunneled dialysis catheters are prone to frequent malfunction and infection. Catheter thrombosis occurs despite prophylactic anticoagulant locks. Catheter thrombi may also serve as a nidus for catheter infection, thereby increasing the risk of bacteremia. Thus, heparin coating of catheters may reduce thrombosis and infection. This study evaluated whether heparin-coated hemodialysis catheters have fewer infections or greater cumulative survival than noncoated catheters. Design, setting, participants, & measurements: We retrospectively queried a prospective access database to analyze the outcomes of 175 tunneled dialysis catheters placed in the internal jugular vein, including 89 heparin-coated catheters and 86 noncoated catheters. The primary outcome was cumulative catheter survival, and the secondary outcome was infection-free catheter survival. Results: The two patient groups were similar in demographics and clinical and catheter features. Catheter-related bacteremia occurred less frequently with heparin-coated catheters than with noncoated catheters (34 versus 60%, P < 0.001). Cumulative catheter survival was similar in heparin-coated and noncoated catheters (hazard ratio, 0.87; 95% confidence interval, 0.55 to 1.36; P = 0.53). On multiple variable survival analysis including catheter type, age, sex, diabetes, coronary artery disease, peripheral vascular disease, cerebrovascular disease, catheter location, and previous catheter, only catheter location predicted cumulative catheter survival (hazard ratio, 2.03; 95% Cl, 1.27 to 3.25, with the right internal jugular location being the reference group, P = 0.003). The frequency of thrombolytic instillation was 1.8 per 1000 catheter-days in both groups. Conclusions: Heparin coating decreases the frequency of catheter-related bacteremia but does not reduce the frequency of catheter malfunction. Clin J Am Soc Nephrol 4: 1787-1790, 2009. doi: 10.2215/CJN.03920609
引用
收藏
页码:1787 / 1790
页数:4
相关论文
共 36 条
  • [31] Does UV Light as an Adjunct to Conventional Treatment Improve Healing and Reduce Infection in Wounds? A Systematic Review
    Oropallo, Alisha
    Goodwin, Ashley
    Morrissey, MaKenzie
    Del Pin, Christina
    Rao, Amit
    ADVANCES IN SKIN & WOUND CARE, 2021, 34 (04) : 1 - 7
  • [32] Early Nephrology Referral 6 Months Before Dialysis Initiation Can Reduce Early Death But Does Not Improve Long-Term Cardiovascular Outcome on Dialysis
    Hayashi, Terumasa
    Kimura, Tomonori
    Yasuda, Keiko
    Sasaki, Koichi
    Obi, Yoshitsugu
    Nagayama, Harumi
    Ohno, Motoki
    Uematsu, Kazusei
    Tamai, Takehiro
    Nishide, Takahiro
    Rakugi, Hiromi
    Isaka, Yoshitaka
    CIRCULATION JOURNAL, 2016, 80 (04) : 1008 - +
  • [33] Does antimicrobial coating and impregnation of urinary catheters prevent catheter-associated urinary tract infection? A review of clinical and preclinical studies
    Majeed, Aneela
    Sagar, Fnu
    Latif, Azka
    Hassan, Hamza
    Iftikhar, Ahmad
    Darouiche, Rabih O.
    Al Mohajer, Mayar
    EXPERT REVIEW OF MEDICAL DEVICES, 2019, 16 (09) : 809 - 820
  • [34] A Heparin-Coated Dialysis Filter (AN69 ST) Does Not Reduce Clotting during Hemodialysis when Compared to a Conventional Polysulfone Filter (F x 8)
    Sagedal, Solbjorg
    Witczak, Bartlomiej J.
    Osnes, Kare
    Hartmann, Anders
    Os, Ingrid
    Eikvar, Lars
    Klingenberg, Olav
    Brosstad, Frank
    BLOOD PURIFICATION, 2011, 32 (03) : 151 - 155
  • [35] Does negative pressure wound therapy reduce the odds of infection and improve health-related quality of life in patients with open fractures?
    Atwan, Y.
    Sprague, S.
    Slobogean, G. P.
    Bzovsky, S.
    Jeray, K. J.
    Petrisor, B.
    Bhandari, M.
    Schemitsch, E.
    BONE & JOINT OPEN, 2022, 3 (03): : 189 - 195
  • [36] Rifampicin does not reduce moxifloxacin concentrations at the site of infection and may not improve treatment outcome of a one-stage exchange surgery protocol of implant-associated osteomyelitis lesions in a porcine model
    Vittrup, Sofus
    Jensen, Louise Kruse
    Hartmann, Katrine Top
    Aalbaek, Bent
    Hanberg, Pelle
    Slater, Josefine
    Hvistendahl, Magnus Andreas
    Stilling, Maiken
    Jorgensen, Nis Pedersen
    Bue, Mats
    APMIS, 2024, 132 (03) : 198 - 209